In 2015, an FDA inspection at a research site in the United States uncovered something that no amount of corrective action could fully repair. Laboratory values recorded in the case report forms did not match the values in the laboratory reports. Vital signs documented in source worksheets had no corresponding entries in the electronic health record. Dates on informed consent forms preceded the dates those forms had been approved by the IRB. The investigators were not sloppy. They had fabricated data.

The consequences were swift. The FDA issued a Form 483 listing the observations. A Warning Letter followed. The principal investigator was placed on the FDA's clinical investigator disqualification list -- effectively ending a research career built over two decades. The site was terminated from the study. Fourteen months of participant data were excluded from the sponsor's regulatory submission. And the participants themselves -- people who had consented to an experimental treatment believing their experience would advance medical knowledge -- learned that their sacrifice had produced nothing usable.

This was not an isolated incident. It was not even unusual. FDA inspection data reveal that data integrity findings account for a substantial proportion of all Form 483 observations at clinical investigator sites. The categories repeat with depressing regularity: fabrication, systematic documentation delays, selective reporting, inadequate oversight. Each category violates specific data integrity criteria you studied in the first lesson of this module. And each produces consequences that extend far beyond the person who committed the violation.

In 2015, an FDA inspection at a research site in the United States uncovered something that no amount of corrective action could fully repair. Laboratory values recorded in the case report forms did not match the values in the laboratory reports. Vital signs documented in source worksheets had no corresponding entries in the electronic health record. Dates on informed consent forms preceded the dates those forms had been approved by the IRB. The investigators were not sloppy. They had fabricated data.

The consequences were swift. The FDA issued a Form 483 listing the observations. A Warning Letter followed. The principal investigator was placed on the FDA's clinical investigator disqualification list -- effectively ending a research career built over two decades. The site was terminated from the study. Fourteen months of participant data were excluded from the sponsor's regulatory submission. And the participants themselves -- people who had consented to an experimental treatment believing their experience would advance medical knowledge -- learned that their sacrifice had produced nothing usable.

This was not an isolated incident. It was not even unusual. FDA inspection data reveal that data integrity findings account for a substantial proportion of all Form 483 observations at clinical investigator sites. The categories repeat with depressing regularity: fabrication, systematic documentation delays, selective reporting, inadequate oversight. Each category violates specific data integrity criteria you studied in the first lesson of this module. And each produces consequences that extend far beyond the person who committed the violation.